• THE COMPANY
  • Executive Summary
  • The Team
• TECHNOLOGY
  • hI-con1™
  • hI-con1™ and Wet AMD
  • hI-con1™ and Cancer
• PLANS FOR CLINICAL STUDIES
• OPERATIONAL OVERVIEW
  • Manufacturing
  • GLP Safety Studies
  • Analytics
  • Regulatory Affairs
  • Intellectual Property
• REFERENCES
• CONTACT

REFERENCES

The following is a list of publications relevant to hI-con1 ’s activity and mechanism of action.

1. Alessi P, Ebbinghaus C, Neri D: Molecular targeting of angiogenesis. Biochim Biophys Acta 2004, 1654:39-49.

2. Bora PS, Hu Z, Tezel TH, Sohn JH, Kang SG, Cruz JMC, Bora NS, Garen A, Kaplan HJ. Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. Proceedings of the National Academy of Sciences 2003 100: 2679-2684.

3. Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD. hI-con1™, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. British Journal of Cancer. 2010 103:812-9.

4. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-15.

5. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134:1087-97.

6. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proceedings of the National Academy of Sciences 2000 97: 9221-9225.

7. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proceedings of the National Academy of Sciences 2001 98: 12180-12185.

8. Hu Z, Li J. Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. BMC Immunology 2010; 11:49.

9. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proceedings of the National Academy of Sciences 1999 96: 8161-8166.

10. Kasthuri RS, Taubman MB, Mackman N (2009) Role of Tissue Factor in Cancer. J Clin Oncol 27: 4834-4838.

11. Kiilgaard JF, Andersen MV, Wiencke AK, Scherfig E, la Cour M, Tezel TH, Prause JU. A new animal model of choroidal neovascularization. Acta Ophthalmol Scand 2005;83:697-704.

12. Krikun G, Hu Z, Osteen K, Bruner-Tran KL, Schatz F, Taylor HS, Toti P, Arcuri F, Konigsberg W, Garen A, et al: The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol 2010, 176:1050-6.

13. Patterson DM, Rustin GJ: Vascular damaging agents. Clin Oncol (R Coll Radiol) 2007, 19:443-56

14. Pilat MJ, Lorusso PM: Vascular disrupting agents. J Cell Biochem 2006, 99:1021-39.

15. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MA, Marme D, Lorusso PM: Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005, 11:416-20.

16. Tezel TH, Bodek E, Sonmez K, Kaliappan S, Kaplan HJ, Hu Z, Garen A. Targeting Tissue Factor for Immunotherapy of Choroidal Neovascularization by Intravitreal Delivery of Factor VII-Fc Chimeric Antibody. Ocular Immunology and Inflammation 2007 15:3-10.

17. Wang B, Chen YB, Ayalon O, Bender J, Garen A. Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement. Proceedings of the National Academy of Sciences 1999 96: 1627-1632